Business Description
AtaiBeckley Inc
NAICS : 541714
SIC : 2834
ISIN : NL0015000DX5
Total Employee Number:
99Description
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 115.38 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.92 | |||||
Beneish M-Score | 1.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 162.1 | |||||
3-Year EBITDA Growth Rate | -50 | |||||
3-Year EPS without NRI Growth Rate | 0.6 | |||||
3-Year FCF Growth Rate | 9.5 | |||||
3-Year Book Growth Rate | -27 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.66 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 46.42 | |||||
14-Day RSI | 45.35 | |||||
6-1 Month Momentum % | -4.31 | |||||
12-1 Month Momentum % | 63.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.02 | |||||
Quick Ratio | 10.02 | |||||
Cash Ratio | 9.24 | |||||
Days Sales Outstanding | 80.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.8 | |||||
Shareholder Yield % | -11.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3531.08 | |||||
Net Margin % | -19019.44 | |||||
EBITDA Margin % | -18982.14 | |||||
FCF Margin % | -3190.92 | |||||
OCF Margin % | -3031.61 | |||||
ROE % | -378.61 | |||||
ROA % | -280.53 | |||||
ROIC % | -179.49 | |||||
3-Year ROIIC % | 1116.49 | |||||
ROC (Joel Greenblatt) % | -12100.96 | |||||
ROCE % | -311.77 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 314.23 | |||||
PB Ratio | 7.52 | |||||
Price-to-Tangible-Book | 7.49 | |||||
EV-to-EBIT | -1.92 | |||||
EV-to-EBITDA | -1.93 | |||||
EV-to-Revenue | 365.62 | |||||
EV-to-Forward-Revenue | 333.85 | |||||
EV-to-FCF | -11.44 | |||||
Price-to-GF-Value | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 8.2 | |||||
| Price-to-Net-Cash | 9.07 | |||||
Earnings Yield (Greenblatt) % | -52.08 | |||||
FCF Yield % | -7.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AtaiBeckley Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.996 | ||
| EPS (TTM) (€) | -1.906 | ||
| Beta | 2.0348 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 1.36 | ||
| Volatility % | 102.88 | ||
| 14-Day RSI | 45.35 | ||
| 14-Day ATR (€) | 0.000013 | ||
| 20-Day SMA (€) | 3.445 | ||
| 12-1 Month Momentum % | 63.81 | ||
| 52-Week Range (€) | 1.776 - 5.81 | ||
| Shares Outstanding (Mil) | 368.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AtaiBeckley Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AtaiBeckley Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 141 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 51 days | ||
| 7th Annual HCW Neuro Perspectives Hybrid Conference | 2026-06-15 07:00 | 3.45 (+0.00%) | ||
| Oppenheimer CNS and Neuro-Muscular Summit | 2026-06-10 13:35 | 3.45 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 12:15 | 3.45 (+0.00%) | ||
| General meeting for 2026 | 2026-05-15 18:00 | 3.45 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 3.45 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.45 (+0.00%) | ||
| General meeting for 2026 | 2026-05-04 11:00 | 3.45 (+0.00%) | ||
| Annual report for 2025 | 2026-03-17 | 3.45 (+0.00%) |
Show
Entries
AtaiBeckley Inc Frequently Asked Questions
What is AtaiBeckley Inc(STU:B72)'s stock price today?
The current price of STU:B72 is €3.45. The 52 week high of STU:B72 is €5.81 and 52 week low is €1.78.
When is next earnings date of AtaiBeckley Inc(STU:B72)?
The next earnings date of AtaiBeckley Inc(STU:B72) is 2026-08-14 Est..
Does AtaiBeckley Inc(STU:B72) pay dividends? If so, how much?
AtaiBeckley Inc(STU:B72) does not pay dividend.
Press Release
Articles on AtaiBeckley Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers